SCHEMBL4764020

SCHEMBL4764020

c1ccc(COc2ccc(Nc3ncnc4[nH]c(-c5ccc(CN6CCCC6)cc5)cc34)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.60
AURKB Q96GD4 2/20 0.60
INCENP Q9NQS7 1/20 0.60
PRMT5 O14744 16/20 0.58
STK10 O94804 1/20 0.53
MAP4K4 O95819 1/20 0.53
ABL1 P00519 1/20 0.53
ERBB2 P04626 1/20 0.53
YES1 P07947 1/20 0.53
RET P07949 1/20 0.53
PDGFRB P09619 1/20 0.53
BCR P11274 1/20 0.53
FLT1 P17948 1/20 0.53
ERBB3 P21860 1/20 0.53
WEE1 P30291 1/20 0.53
KDR P35968 1/20 0.53
ABL2 P42684 1/20 0.53
NEK3 P51956 1/20 0.53
LIMK1 P53667 1/20 0.53
LIMK2 P53671 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4771238 0.99 EGFR (0.59) EGFRAURKBINCENPPRMT5STK10
SCHEMBL4764456 0.92 PRMT5 (0.66) EGFRAURKBINCENPPRMT5
SCHEMBL4766562 0.92 PRMT5 (0.69) EGFRAURKBINCENPPRMT5STK10
SCHEMBL4763910 0.92 PRMT5 (0.66) EGFRAURKBINCENPPRMT5STK10
SCHEMBL4764644 0.87 PRMT5 (0.67) EGFRAURKBINCENPPRMT5TTBK1
SCHEMBL4763947 0.87 PRMT5 (0.64) EGFRAURKBINCENPPRMT5ERBB2
SCHEMBL4764411 0.85 EGFR (0.53) EGFRAURKBINCENPPRMT5ERBB2
SCHEMBL4764558 0.83 EGFR (0.63) EGFRAURKBINCENPPRMT5ERBB2
SCHEMBL4768646 0.81 EGFR (0.61) EGFRAURKBINCENPPRMT5ERBB2
SCHEMBL4765652 0.80 EGFR (0.56) EGFRAURKBINCENPPRMT5ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1416935-B1 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2008-03-12 EP claimed
US-7244729-B2 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives NOVARTIS AG (CH) 2007-07-17 US claimed
US-20040248911-A1 7H-pyrrolo[2,3-d]pyrimidine derivatives BOLD GUIDO (CH) 2004-12-09 US claimed
US-20040242600-A1 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives NOVARTIS AG (CH) 2004-12-02 US claimed
CN-1538847-A 4-amino-6-phenyl-pyrrolo [2, 3-d ] pyrimidine derivatives ��˹��ŵ�� 2004-10-20 CN claimed
EP-1416935-B1 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2008-03-12 EP disclosed
CN-1538847-A 4-amino-6-phenyl-pyrrolo [2, 3-d ] pyrimidine derivatives ��˹��ŵ�� 2004-10-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248911-A1 7H-pyrrolo[2,3-d]pyrimidine derivatives DPYD, DHPS, TYMP EGFR 3391/4885AURKB 964/4885INCENP 1796/4885
US-20040242600-A1 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives DPYD, TYMP, TYMS EGFR 2694/4885AURKB 818/4885INCENP 2752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.